Navigation Links
NIH-funded genetic sequencing tool speeds drug discovery, disease diagnostics
Date:10/31/2012

Today physicists at Wake Forest University and NanoMedica, their biotechnology company partner, received a $700,000 grant from the National Institutes of Health (NIH) to bring to market a new drug-discovery tool using next-generation genetic sequencing.

The technology, Next-Gen Lab-on-Bead, would be the first bead-based drug-discovery tool to use the latest genetic sequencing technologies, making drug and diagnostics discovery significantly more efficient.

Pharmaceutical companies would use the technology as a sort of Google search for new drugs sending the scientists a protein marker of the disease for which they want to find a treatment, and letting Next-Gen Lab-on-Bead test millions of possibilities all at once.

"Next-gen is much faster and cheaper, and no one is using it for drug discovery as far as we know," said Martin Guthold, associate professor of physics and co-inventor of Next-Gen Lab-on-Bead. "It miniaturizes and massively parallelizes sequencing on beads in little wells, so we can do millions of sequencing actions in unison to find potential drug candidates to treat a specific disease."

The NIH awarded the funding through its Small Business Innovation Research program, so Wake Forest will share the funds with NanoMedica, a Winston-Salem company that has licensed the patent for Next-Gen Lab-on-Bead.

The technology uses a roughly one-inch-square chip, similar to a computer chip. A football-shaped area in the middle of the chip is filled with millions of wells. Each well contains a bead, to which the researchers attach a potential drug molecule.

"Each chip contains millions of potential drug candidates," Guthold said. "We know the position and identity of each, because we can associate a potential drug molecule with the sequence in each well."

To find a disease-drug match, a pharmaceutical company would supply the target for instance, a protein called Src kinase associated with many cancers. The researchers would combine the fluorescently labeled protein with a neutral solution and flow it over the chip.

If a well glows fluorescently, indicating that the protein target bound to the bead in the well, it contains a drug candidate that is potentially useful in treating the disease. The pharmaceutical company then can begin testing the drug in the lab.

Though the Wake Forest-NanoMedica research team has focused on drug discovery, Next-Gen Lab-on-Bead also could be used for more accurate, speedy medical diagnoses.

"If you want to see if a biopsy is cancerous, you could use diagnostic molecules that were discovered with this technology. If a biopsy sample binds to certain diagnostic molecules, then it's cancerous," Guthold said.

The research team includes Keith Bonin, Jed Macosko and Jason Gagliano of the Wake Forest physics department.

Wake Forest and NanoMedica also have received a two-year, $160,000 Collaborative Funding Grant from the North Carolina Biotechnology Center to refine Next-Gen Lab-on-Bead for commercial use.

"We have made a major commitment to purchasing expensive equipment that's beyond the realm of most startups, and that's a risk we took because we are confident that applying next-gen sequencing to drug discovery is really novel," said Roger Cubicciotti, NanoMedica president/CEO.

According to a recent report by Frost & Sullivan, next-generation genetic sequencing is expected to boom in the next five years as researchers explore drug-discovery and diagnostic applications. That will make it one of the fastest-growing markets in the biomedical industry, the report says.


'/>"/>

Contact: Katie Neal
nealkc@wfu.edu
336-758-6141
Wake Forest University
Source:Eurekalert

Related biology news :

1. NIH-funded researchers restore sense of smell in mice using genetic technique
2. NIH-funded study examines use of mobile technology to improve diet and physical activity behavior
3. Global genome effort seeks genetic roots of disease
4. Social factors trump genetic forces in forging friendships, CU-led study finds
5. Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine
6. Researchers identify genetic basis of cardiac, craniofacial birth defects
7. Scientists deepen genetic understanding of MS
8. Far from random, evolution follows a predictable genetic pattern, Princeton researchers find
9. Pitt biologist receives $2 million to study genetic diversity of plants worldwide
10. Scientists uncover mechanism by which plants inherit epigenetic modifications
11. Men and women are different in terms of genetic predispositions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , ... December 02, 2016 , ... Robots will storm ... on December 3rd, 2016. The event, which is held on the United Nations ... helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering with NTI ...
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... York , November 30, 2016 ... as a few players hold a dominant share in ... Charles River Laboratories International, Inc., and Merck KGaA, held ... in 2015. Transparency Market Research observes that these companies ... focused on development products that are do not require ...
(Date:11/30/2016)... SEATTLE , Nov. 30, 2016  The ... Allen Cell Collection: the first publicly available collection ... stem cells that target key cellular structures with ... Medical Research, these powerful tools are a crucial ... cells to better understand what makes human cells ...
Breaking Biology Technology: